WallStSmart
DFTX

Definium Therapeutics, Inc.

NASDAQ: DFTX · HEALTHCARE · BIOTECHNOLOGY

$21.16
-4.23% today

Updated 2026-06-05

Market cap
$2.64B
P/E ratio
P/S ratio
EPS (TTM)
$-2.50
Dividend yield
52W range
$6 – $26
Volume
2.6M

WallStSmart proprietary scores

25
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
6.0
Quality
B
3.0
Profitability
D
5.0
Valuation
C+
2/9
Piotroski F-Score
Weak
Altman Z-Score
Industry rank
View all highly rated stocks (75+) →203 stocks currently score above 75

Price targets

Analyst target
$39.87
+88.42%
12-Month target
Intrinsic (DCF)
Margin of safety
4 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-42.63M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-56.80M$-95.73M$-108.68M$-183.79M$-77.10M
EPS$-2.50
Free cash flow$-50.14M$-64.36M$-79.13M$-131.56M$-42.63M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
DFTX$2.64B254.33.05.06.0Avoid
LLY$1.01T7610.010.04.36.0Strong Buy
JNJ$567.28B574.79.03.36.0-67.79%Buy
ABBV$391.50B634.08.04.05.0-48.06%Buy
UNH$373.28B545.35.54.05.5-24.80%Buy
NVS$289.19B493.39.03.34.5-62.62%Hold

Smart narrative

Definium Therapeutics, Inc. trades at $21.16. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.

Frequently asked questions

What is Definium Therapeutics, Inc.'s stock price?

Definium Therapeutics, Inc. (DFTX) trades at $21.16.

Is Definium Therapeutics, Inc. overvalued?

Definium Therapeutics, Inc. carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Definium Therapeutics, Inc. (DFTX)?

The 12-month analyst consensus target is $39.87, about 88.4% above the current $21.16. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio
ROE-85.19%
Beta2.38
50D MA$22.54
200D MA$16.21
Shares out0.11B
Float0.11B
Short ratio
Avg volume2.6M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years